Tumor immune microenvironment score predicts efficacy of immune checkpoint inhibitors-based regimens in advanced non-small cell lung cancer
PIE represents a clinically relevant, transcriptome-based predictive model for evaluating the benefit of ICI treatment in advanced NSCLC. With further prospective validation, PIE may facilitate personalized patient selection and guide the development of novel strategies to overcome primary resistance.
Authors
- Zhe Huang (ORCID: https://orcid.org/0000-0002-3524-2806)
- Qinqin Xu (ORCID: https://orcid.org/0000-0002-1359-8895)
- Huan Yan
- Haoyue Qin
- Zhaohui Ruan
- Fang Tian (ORCID: https://orcid.org/0000-0002-5631-7125)
- Yongchang Zhang (ORCID: https://orcid.org/0000-0002-6829-7176)
- Jiacheng Dai (ORCID: https://orcid.org/0009-0006-3000-9753)
- Li Xing (ORCID: https://orcid.org/0000-0002-4186-7909)
- Yuda Zhang
- Jin Wang (ORCID: https://orcid.org/0009-0006-3212-8326)
- Liang Zeng (ORCID: https://orcid.org/0000-0002-4755-775X)
- Yangqian Chen
- Changbin Zhu
- Nong Yang
Institutions
- Qinghai University (CN)
- Central South University (CN)
- Xiamen University (CN)
- Second People Hospital of Hunan (CN)
- Hunan Cancer Hospital (CN)
- Dian Diagnostics (China) (CN)
- Qinghai Provincial Peoples Hospital (CN)
- Xiamen Tobacco Industry (China) (CN)
- University of South China (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1186/s12967-025-07408-z
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- Central South University
- Sichuan University
- Xiangya Hospital, Central South University
- West China Hospital, Sichuan University